Syndax Pharmaceuticals

Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of first-in-class therapies in areas of high unmet need. Highlights of the Company’s pipeline include a highly selective menin inhibitor for acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus-host disease. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. Syndax corporate headquarters are in Waltham, MA.